

1 Article

2 **Comparative analysis of immune-associated genes in COVID-19,** 3 **cardiomyopathy and venous thromboembolism**

4
5 **Grant Castaneda^{1,2,†}, Abby C Lee^{1,2,†}, Wei Tse Li^{1,2}, Chengyu Chen^{1,2}, Jaideep Chakladar^{1,2}, Eric Y.**
6 **Chang³, and Weg M. Ongkeko^{1,2,*}**

7 ¹ Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California, San Diego,
8 La Jolla, California, United States of America

9 ² Research Service, VA San Diego Healthcare System, San Diego, California, CA, 92161, US

10 ³ Department of Radiology, University of California, San Diego, California CA, 92093, USA

11 * Correspondence: rongkeko@health.ucsd.edu; Tel.: (858) 552-8585 X 7165

12 † Authors contributed equally

13 14 **Abstract**

15 As of 28 August 2020, there have been 5.88 million Coronavirus Disease 2019 (COVID-
16 19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an
17 effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its
18 varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for
19 the allocation of valuable healthcare resources during this pandemic. Current research has shown
20 that there is a higher prevalence of cardiovascular comorbidities amongst patients with severe
21 COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease and poorer
22 prognosis is poorly understood. We believe that pre-existing immune dysregulation that
23 accompanies cardiovascular disease predisposes patients to a harmful inflammatory immune
24 response, leading to their higher risk of severe disease. Thus, in this project, we aim to
25 characterize immune dysregulation in patients with cardiomyopathy, venous thromboembolism
26 and COVID-19 patients by looking at immune-associated gene dysregulation, immune infiltration
27 and dysregulated immunological pathways and gene signatures.

28
29 **Keywords:** COVID-19; cardiovascular disease; cardiomyopathy; venous thromboembolism

30 **1. Introduction**

31 In December 2019, widespread infection by severe acute respiratory syndrome
32 coronavirus 2 (SARS-CoV-2), was reported in Wuhan, Hubei Province, China [1]. Since then,
33 SARS-CoV-2 has spread rapidly throughout China and across the world and was declared a
34 global pandemic by the World Health Organization (WHO) on March 11, 2020 [2]. Infection by
35 SARS-CoV-2 causes Coronavirus Disease 2019 (COVID-19). Clinical outcomes vary widely
36 amongst patients [3-5]. Common symptoms of COVID-19 include fever, cough, fatigue, slight
37 dyspnoea, sore throat, headache, conjunctivitis and gastrointestinal issues [6,7]. Patients with
38 more severe cases of COVID-19 experience respiratory failure and pneumonia that may be
39 deadly [8]. Current research suggests that patients with existing comorbidities, such as
40 hypertension, cardiovascular disease, diabetes, or obesity are more likely to develop severe
41 COVID-19 [9-11]. COVID-19 has also been known to induce myocardial injury, arrhythmia, acute
42 coronary syndrome and venous thromboembolism (VTE) [12-14]. Development of cardiovascular
43 damage has been attributed to cytokine storms triggered by SARS-CoV-2 infection that can cause
44 multi-organ damage [15,16]. In addition, COVID-19 patients experience coagulation
45 abnormalities, which may lead to increased risk of thromboembolic events [17]. In all, current
46 research suggests a link between cardiovascular disease and COVID-19. However, how
47 cardiovascular disease results in poorer COVID-19 prognosis and higher mortality rates remains
48 unclear.

49 Cardiomyopathy is a cardiovascular disease where the heart muscles become inflamed,
50 making it difficult for the heart to pump blood throughout the body. One of the most common forms
51 of cardiomyopathy is dilated cardiomyopathy (DCM), where the ventricles of the heart are
52 enlarged [18]. The primary cause of DCM is unclear. However, DCM can be caused by viral
53 infections that target the heart muscles and can thereby cause heart attacks or coronary artery
54 disease. When DCM is induced by a heart attack or coronary artery disease it is known as
55 ischemic cardiomyopathy (ICM). By promoting an inflammatory milieu and fibrosis, cytokines and
56 inflammasomes play a role in cardiomyopathy pathogenesis, which suggests a potential
57 connection between cardiomyopathy and COVID-19 [19-21].

58 VTE includes both deep vein thrombosis (DVT), where a blood clot forms in a deep vein,
59 and pulmonary embolism (PE), where a clot dislodges and travels to the lungs via the
60 bloodstream, blocking pulmonary circulation. It is well-established that the immune system plays
61 a role in DVT pathogenesis, and restriction of venous blood flow leads to the recruitment of
62 neutrophils, monocytes and platelets [22-24]. Given that higher levels of monocytes and
63 neutrophils have been observed in COVID-19 patients requiring ICU hospitalization, it is possible
64 that such pre-existing immune dysregulation in COVID-19 VTE patients makes them more likely
65 to progress to severe disease [25-27].

66 In this project, we aim to characterize dysregulation of the immune landscape in patients
67 with cardiomyopathy, with VTE and with COVID-19. We analyzed the expression of cytokine
68 genes and inflammasome-related genes using RNA-sequencing data obtained from COVID-19
69 and cardiomyopathy patients. We also analyzed the extent of immune infiltration and the
70 enrichment of immunological pathways and signatures. By comparing these features of the
71 immune system, we hope to gain a more comprehensive understanding of the effects of
72 cardiovascular disease on the immune system that leave patients more vulnerable to severe
73 COVID-19.

74 **2. Results**


76 *2.1 Similarities in immune-associated gene dysregulation landscape in COVID-19 and* 77 *cardiomyopathy samples*

78 We obtained gene expression sequencing data from samples of COVID-19 patients and
79 cardiomyopathy patients and performed differential expression analysis to identify genes
80 dysregulated between patient cohorts (edgeR, $p < 0.05$). Gene dysregulation was determined by
81 comparing COVID-19 samples to normal samples (from patients without COVID-19) and
82 cardiomyopathy samples to normal samples (from patients with no major cardiovascular
83 diseases). Cardiomyopathy samples were separated based on whether patients had ischemic or
84 dilated cardiomyopathy. The two groups were individually compared against samples from
85 patients with no major cardiovascular disease. Cardiomyopathy and corresponding normal
86 samples were obtained from the left ventricle of deceased patients, while COVID-19 and
87 corresponding normal samples were platelet samples. However, we expect to capture genetic
88 material from circulating immune cells in both of these samples.

89 Only immune associated (IA) differentially expressed genes were retained for further
90 analysis, in order to compare the immune profile of patients with COVID-19 to that of patients with
91 cardiomyopathy. We found that there was significant overlap between COVID-19 patient IA gene
92 expression and that of both ischemic and dilated cardiomyopathy patients. About half of the IA
93 genes dysregulated in COVID-19 are also dysregulated in either or both types of cardiomyopathy
94 (Figure 1A). We grouped these genes into cytokine-related and inflammasome-related genes.
95 Cytokine-related genes that are dysregulated in both cardiomyopathy patients and COVID-19
96 patients include chemokines (CCL3, CCL4, CXCL4, etc), interleukins or interleukin receptors

97 (IL15, IL20RA, etc.), or genes in the TGFB family. Inflammasome-related genes include genes in
 98 the caspase family (CASP2, CASP9, etc), MAPK-related genes, and NFkB regulators (IKBKG,
 99 NFKBIA, etc.). IA gene dysregulation is very similar between dilated and ischemic
 100 cardiomyopathies. We observed that a significant number of cytokines, interleukins, TGFB-
 101 related genes, and TNF-related genes were dysregulated in either types of cardiomyopathies but
 102 not in COVID-19 (Figure 1A).

103 Figure 1: Comparing ICM, DCM and COVID-19 patients. (A) Summary of commonly dysregulated cytokine and



104 inflammasome-related genes in COVID-19 and ICM/DCM patients. Cytokines are in blue and inflammasome-related
 105 genes are in red. (B) Barplots of the log2 fold change of significantly dysregulated cytokine genes in COVID-19 and
 106 ICM/DCM patients. (C) Heatmaps of inflammasome-related genes in COVID-19 and ICM/DCM patients. (D) Radar
 107 plots comparing immune cell infiltration between COVID-19 and ICM/DCM patients.

108
 109 Interestingly, we found that most genes dysregulated in both COVID-19 and
 110 cardiomyopathy, were dysregulated to a greater degree in COVID-19 samples than in
 111 cardiomyopathy samples. This trend was observed for TGFB3, CCL4, IL15, and IL20RA in both
 112 ischemic cardiomyopathy samples vs COVID-19 samples and dilated cardiomyopathy samples
 113 vs. COVID-19 samples (Figure 1B). Furthermore, the expression of these dysregulated genes

114 appeared to be very similarly dysregulated in COVID-19 samples and in corresponding healthy
115 samples, with similar levels of gene expression for individual patients in each group and a distinct
116 upregulation trend in COVID-19 samples (Figure 1C). In contrast, these genes' expression in
117 cardiomyopathy samples and corresponding healthy samples are only sometimes similar, without
118 overwhelming differences in expression levels between the two cohorts (Figure 1C). Therefore,
119 we believe that these dysregulated genes are dysregulated to a greater degree in COVID-19 than
120 in cardiomyopathy.

121 The inflammasome-associated genes dysregulated in both COVID-19 and cardiomyopathy are
122 upregulated in both conditions (Figure 1C), suggesting that COVID-19 and cardiomyopathy may
123 upregulate inflammation through similar pathways.

124


125 *2.2 Comparison of immune cell population abundance in COVID-19 vs. cardiomyopathy patients*

126 Using Cibersortx, we inferred the percent composition of 22 different immune cell types using the
127 gene expression profile of bulk RNA-sequencing data. We discovered that the levels of T cells
128 and B cells were unchanged in healthy vs. COVID-19 patients (Figure 1D). The most noticeable
129 change in immune cell abundance occurs in macrophages for COVID-19 patients, where M0
130 macrophages levels were dramatically reduced, and M1 and M2 macrophages levels were slightly
131 increased (Figure 1D). Both ischemic and dilated cardiomyopathy elicited greater immune cell
132 abundance changes than COVID-19 did, with the changes being more pronounced for ischemic
133 myocardial pathology. The levels of M1 and M2 macrophages also increased in ischemic
134 myocardial pathology, similar to what was observed for COVID-19 (Figure 1D). The levels of T and B
135 cell subtypes changed more dramatically in ischemic and dilated myocardial pathology than in COVID-
136 19. In summary, the levels of inflammatory macrophages increased for both cardiomyopathy and
137 COVID-19 patients, while the levels of other immune cell types did not correlate between the two
138 conditions.

139 *2.3 Evaluation of canonical pathways correlated with genes dysregulated in both COVID-19 and 140 cardiomyopathy*

141 To obtain a deeper understanding of the functions of the dysregulated genes in COVID-19 and
142 cardiomyopathy, we correlated IA gene expression to the dysregulation of canonical biological
143 pathways, obtained from the Molecular Signatures Database (MsigDB) [28]. We analyzed genes
144 that are dysregulated in both COVID-19 and cardiomyopathy to assess if they may dysregulate
145 the common pathways in the two conditions. IRAK2, upregulated in both COVID-19 and ischemic
146 cardiomyopathy, was associated with the upregulation of the FCER1 and TP63 pathways, both
147 of which are associated with inflammation and immune activation (Figure 2A) [29,30]. IRAK2 is a
148 promoter of NFkB signaling [31]. CASP2, also upregulated in COVID-19 and cardiomyopathy, is
149 associated with the downregulation of IFIH, which is capable of recognizing viruses and inducing
150 inflammation [32]. Finally, CYLD is correlated with multiple identical pathways for both COVID-19
151 samples and ischemic cardiomyopathy samples. It is also upregulated in both COVID-19 and
152 cardiomyopathy and was found to correlate with the activation of FGFR2, an important promoter
153 of inflammation [33], and TXA2, a well-known gene that is upregulated in platelets (Figure 2A)
154 [34]. CYLD itself is an inhibitor of inflammation [35]. Since the majority of correlations are between
155 IA genes and pro-inflammatory pathways and signatures, we hypothesize that CYLD may be
156 expressed as a response to attenuate excessive inflammation. We found that the overwhelming
157 majority of pathways that correlated with dysregulated genes in both COVID-19 and dilated
158 cardiomyopathy is associated with CYLD, and these pathways are primarily pro-clotting, pro-cell

159 aggregation, and pro-inflammation (Figure 2B), which reinforces the possibility that CYLD is
 160 released in response to inflammation.



161 Figure 2: Comparing ICM, DCM and COVID-19 patients. **(A)** Barplots showing direction of correlation between
 162 commonly dysregulated genes of ICM and COVID-19 patients and canonical pathways. **(B)** Barplots showing direction
 163 of correlation between commonly dysregulated genes of DCM and COVID-19 patients and canonical pathways.


164

165 **2.4 Similarities in immune-associated gene dysregulation landscape in COVID-19 and venous**
 166 **thromboembolism (VTE) samples**

167 We compared the immune landscape between COVID-19 samples and blood samples from VTE
 168 patients to find similarities in IA gene and pathway expression. VTE patients are further classified
 169 into single occurrence VTE (single VTE) and recurrent VTE. Differential expression was
 170 performed by comparing blood samples for each type of VTE against blood samples from healthy
 171 controls. Compared to the similarities in IA gene dysregulated between COVID-19 and
 172 cardiomyopathy, the similarities between COVID-19 and VTE are much less-pronounced. We
 173 identified two cytokine-associated genes that were dysregulated in both COVID-19 and single
 174 VTE (CCL4 and CD40), and one cytokine-associated gene dysregulated in both COVID-19 and
 175 recurrent VTE (CCL4) (Figure 3A). CCL4 is a recruiter of immune cells, including macrophages,

176 monocytes, and T-cells [36], suggesting that both COVID-19 and VTE may experience increased
 177 recruitment of inflammatory immune cells. The upregulation of CCL4 is much greater in COVID-
 178 19 than in VTE, however (Figure 3B).

179 Two inflammasome-related genes were found to be dysregulated in VTE and COVID-19,
 180 including BCL2L1 and CASP4. Both single and recurrent VTE share the same set of dysregulated
 181 inflammasome-related genes with COVID-19. BCL2L1 is known to be highly upregulated in
 182 inflamed tissue [37], and it is upregulated in COVID-19 and both single and recurrent VTE (Figure
 183 3C). CASP4 directs the noncanonical upregulation of inflammasomes [38]. Interestingly, it is
 184 upregulated in both COVID-19 and recurrent VTE but downregulated in single VTE (Figure 3C),
 185 which potentially suggests that the gene could contribute to the development of recurrent VTE.




186
 187 Figure 3: Comparing single VTE, recurrent VTE and COVID-19 patients. (A) Summary of commonly dysregulated
 188 cytokine and inflammasome-related genes in COVID-19 and single/recurrent VTE patients. Cytokines are in blue and
 189 inflammasome-related genes are in red. (B) Barplots of the log₂ fold change of significantly dysregulated cytokine
 190 genes in COVID-19 and single/recurrent VTE patients. (C) Heatmaps of inflammasome-related genes in COVID-19
 191 and single/recurrent VTE patients. (D) Radar plots comparing immune cell infiltration between COVID-19 and
 192 single/recurrent VTE patients.

193 **2.5 Comparison of immune cell population abundance in COVID-19 vs. VTE patients**

194 Comparing immune cell population abundance between COVID-19 and VTE patients, we found
 195 that naïve B-cells were dramatically reduced in abundance in VTE patients, which is accompanied
 196 by a slight increase in activated plasma B cells (Figure 3D). This may be a sign of adaptive
 197 immune activation.

198 **2.6 Evaluation of canonical pathways correlated with genes dysregulated in both COVID-19 and**
 199 **VTE**

200 We adopted a similar approach as described for COVID-19 vs. cardiomyopathy to examine
 201 canonical pathways correlated with dysregulated genes in both COVID-19 and VTE. BCL2L1 and
 202 CASP4 are the only genes dysregulated in both COVID-19 and VTE and also correlated with the
 203 same pathways in both patient cohorts (Figure 4A,B). BCL2L1 is upregulated in COVID-19 and
 204 both VTE cohorts (Figure 4C). However, the direction of correlation to pathways was the complete
 205 opposite between COVID-19 and recurrent VTE (Figure 4D, E). The high strength of correlation
 206 for each cohort suggests that BCL2L1 is involved in both COVID-19 and recurrent VTE but may
 207 function in opposite ways. On the other hand, CASP4 expression was correlated with over 10



208 Figure 4: Comparing single VTE, recurrent VTE and COVID-19 patients. (A) Summary of common dysregulated genes
 209 correlated with pathways in single VTE and COVID-19. (B) Summary of common dysregulated genes correlated with
 210 pathways in recurrent VTE and COVID-19. (C) Boxplots of CASP4 and BCL2L1 expression in COVID-19 and VTE
 211 cohorts. (D) Barplots showing direction of correlation between CASP4/ BCL2L1 and canonical pathways. (E)
 212 Enrichment plots showing BCL2L1's correlation to pathways is opposite in COVID-19 and recurrent VTE patients.

213
214 pathways in the same direction for both COVID-19 and recurrent VTE (Figure 4D). It is also
215 upregulated in both COVID-19 and recurrent VTE (Figure 4C). The pathways correlated with
216 CASP4 ranges from immune related (antigen processing and cross presentation) to general
217 metabolism-related (ABC transporter, oxidative phosphorylation). Therefore, while it is likely that
218 CASP4 functions similarly in COVID-19 and recurrent VTE. The precise role of CASP4 requires
219 further investigation.
220

221 **3. Discussion**

222
223 In this project, we characterized the immune landscape of cardiomyopathy patients, VTE patients,
224 and COVID-19 patients, drawing parallels between COVID-19 and immune dysregulation
225 mediated by cardiovascular disease. The overlap of numerous dysregulated IA genes between
226 COVID-19 patients and cardiomyopathy patients not only suggests that these patients possess
227 similar inflammatory environments but could also explain why COVID-19 patients with
228 cardiovascular disease have higher mortality rates. Of the four genes (TGFB3, CCL4, IL15, and
229 IL20RA) that were more severely dysregulated in COVID-19 samples compared to
230 cardiomyopathy patients, two have been noted to be dysregulated in COVID-19 patients:
231 proinflammatory cytokine CCL4 was found to be highly expressed in the bronchoalveolar lavage
232 fluid of COVID-19 patients [39], and IL-15 modulates inflammation and plays a role in viral
233 clearance [40,41]. We also found that both cardiomyopathy and COVID-19 patients had elevated
234 levels of inflammatory macrophages, while T and B cell levels changed more significantly in
235 dilated and ischemic cardiomyopathy patients compared to COVID-19 patients. This points to a
236 more robust innate immune response in COVID-19 patients, which is plausible given that research
237 has shown that an excessively inflammatory innate immune response coupled with an impaired
238 adaptive immune response may lead to tissue damage in COVID-19 patients [42,43]. On the
239 contrary, the elevated levels of T and B cells in cardiomyopathy patients indicates a stronger
240 adaptive immune response, which is now being considered an increasingly important factor in the
241 pathogenesis of cardiovascular disease [44-46].
242

243 We analyzed overlapping gene expression pathway dysregulation between cardiomyopathy and
244 COVID-19 patients in order to compare IA profiles between the two patient cohorts. The
245 overlapping genes that displayed significant canonical pathway dysregulation between the
246 cardiomyopathy and COVID-19 cohorts are CYLD, CASP2, IKBKG and IRAK2. CASP2 and
247 IRAK2 are of particular interest due to their involvement in inflammation. CASP2 is a pro-
248 inflammatory gene and IRAK2 promotes NFkB, which ultimately causes inflammation. Both genes
249 are upregulated in DCM, ICM and COVID-19, suggesting that DCM and ICM patients are more
250 susceptible to a worse inflammatory response to COVID-19. Both IRAK2 and CASP2 are directly
251 associated with the dysregulation of inflammation pathways. For instance, IRAK2 is directly
252 associated with the TAP63 pathway in both ICM and DCM versus COVID-19 groups, indicating
253 that one of the effects of IRAK2 in COVID-19 and cardiomyopathy may be increasing
254 inflammation. Similarly, CASP2 is directly associated with the IFIH1 signaling pathway, which is
255 known to be pro-inflammation. Overall, the genes that overlap between cardiomyopathy and
256 COVID-19 appear to act in a pro-inflammatory manner. Increased inflammatory pathway
257 dysregulation may indicate a reason why cardiovascular disease patients experience much worse
258 clinical outcomes, as several studies have shown a worse inflammatory response correlates with
259 severity and death in COVID-19 [47].
260

261 Exploring the immune-association gene dysregulation landscape relationship between VTE and
262 COVID-19 revealed overlapping differentially expression of CCL4, CD40, BCL2L1 and CASP4.

263 Of the cytokines CCL4 and CD40, only CCL4 is commonly dysregulated in single occurring VTE,
264 recurring VTE and COVID-19 patients. CCL4 has been shown to be upregulated in COVID-19
265 patients [48] and in patients who develop cardiovascular disease [49]. Therefore, the upregulation
266 of CCL4 in both VTE and COVID-19 may suggest a mechanism by which some COVID-19
267 patients develop cardiovascular disease post-infection. The inflammasome-related genes
268 dysregulated in both the VTE and COVID-19 cohorts are BCL2L1 and CASP4. BCL2L1 and
269 CASP4 expression are closely tied to inflammatory caspases. CASP4 itself is an inflammatory
270 caspase and it promotes the secretion of pro-inflammatory cytokines [50]. Conversely, BCL2L1
271 inhibits caspase release. With both of these genes being upregulated in VTE and COVID-19,
272 future analysis must be done to examine how these genes function differently in VTE and COVID-
273 19. BCL2L1 and CASP4, both inflammasome-related genes, stood out as the most interesting
274 genes as both displayed significant canonical pathways in both VTE groups, single occurring and
275 recurrent VTE, and COVID-19. However, only in recurring VTE did both BCL2L1 and CASP4
276 display overlapping canonical pathways with COVID-19, while single occurring VTE only had
277 BCL2L1 with overlapping canonical pathways with COVID-19. Most notably, in both COVID-19
278 and single occurring VTE, BCL2L1 expression is negatively correlated to canonical pathway
279 expression, but in recurring VTE they are positively correlated. Thus, we may deduce that a main
280 difference between single and recurrent VTE is the utilization of BCL2L1. The downregulation of
281 BCL2L1 may increase the risk of COVID-19. due to BCL2L1-mediated inhibition of pro-
282 inflammatory caspases. CASP4, on the other hand, only has overlapping significant canonical
283 pathways with COVID-19 in the recurrent VTE cohort. From these overlapping canonical
284 pathways, we could not find a common trend like there was in BCL2L1. However, we could
285 deduce from these pathways that CASP4 functions similarly in both recurrent VTE and COVID-
286 19.

287
288 In conclusion, our study demonstrates that cardiomyopathy and VTE patients display a significant
289 overlap of inflammasome gene expression profiles with that of COVID-19 patients. This may
290 explain why patients with cardiovascular disease are more likely to develop severe COVID-19,
291 and tend to have poorer clinical outcomes [51,52]. Furthermore, we have found that patients with
292 cardiomyopathy display more similar immune dysregulation to COVID-19 patients than VTE
293 patients, which may indicate that COVID-19 patients who have cardiomyopathy are at higher risk
294 of severe COVID-19 than COVID-19 patients with VTE. Our findings also suggest that
295 investigating the relationships between different cardiovascular diseases and COVID-19 disease
296 severity and mortality may be meaningful, and can offer greater insight into COVID-19 immune
297 dysregulation. However, we recognize our study has several limitations. We had limited COVID-
298 19 platelet data, specifically normal patients. Thus, our differential expression analysis may have
299 been impacted, and the statistical power of our analysis is reduced. However, the direction of
300 dysregulation of many of the genes we identified were consistent with existing literature.
301 Additionally, we used platelet data, instead of blood samples. In order to validate our results, *in*
302 *vitro* and *in vivo* experiments can be done in the future. Despite these limitations, we believe our
303 study advances our understanding of the relationship between cardiovascular disease and
304 COVID-19.

305

306 **4. Methods and Materials**

307 *Downloading Data*

308 RNA-sequencing data was obtained from the following datasets: GSE116250, GSE19151
309 and SRP262885 (8) [53-55]. GSE116250, provided by Sweet et. al, consists of RNA-sequencing
310 of human left ventricular samples from 14 patients with no major cardiac history (non-failing), 37
311 patients with dilated cardiomyopathy and 13 patients with ischemic cardiomyopathy. The mean
312 age of patients with dilated and ischemic cardiomyopathy was 49 and 56 years respectively.

313 GSE19151, provided by Lewis et. al, consists of high-throughput sequencing of whole blood
314 samples from 63 healthy controls, 23 patients with single event VTE, 17 patients with recurrent
315 event VTE on warfarin. The mean age of patients with single VTE and recurrent VTE was 43.8
316 and 55.7 years respectively. Lastly, SRP262885 consists of RNA-sequencing data of platelets
317 from 10 COVID-19 subjects and 5 healthy controls. The mean age of COVID-19 patients and
318 healthy controls is 51.1 and 43.8 respectively.

319

320 *Differential Expression*

321 Differential expression analysis was employed to compare the expression of genes
322 between diseased and normal individuals. For the cardiomyopathy and venous thrombosis
323 cohorts, a Kruskal-Wallis analysis test was used to determine the differentially expressed genes,
324 and genes with $p < 0.05$ were considered significantly dysregulated. Differential expression was
325 applied to the COVID-19 platelet data to determine the genes that were differentially expressed
326 ($p < 0.05$).

327

328 *GSEA*

329 To correlate gene expression to immune-associated signatures, Gene Set Enrichment
330 Analysis (GSEA) was utilized. Pathways were chosen from the C2:CP set of signatures from the
331 Molecular Signatures Database [28]. Signatures that were significantly enriched were those with
332 a nominal p-value < 0.05 .

333

334 *CIBERSORTx*

335 The CIBERSORTx algorithm was used to deconvolute RNA-sequencing data to estimate
336 the infiltration levels of 22 immune cell types [56]. These immune cell types include: naïve B-cells,
337 memory B-cells, plasma cells, CD8 T-cells, CD4 naïve T-cells, CD4 memory resting T-cells, CD4
338 memory activated T-cells, follicular helper T-cells, regulatory T-cells, gamma-delta T-cells, resting
339 NK cells, activated NK cells, monocytes, M0-M2 macrophages, resting dendritic cells, activated
340 dendritic cells, resting mast cells, activated mast cells, eosinophils, and neutrophils.

341

342 **Author Contributions:** Conceptualization, W.M.O; methodology, W.T.L and W.M.O.; software,
343 N/A; formal analysis, A.C.L, G.C, and C.C; investigation, A.L. and G.C.; resources, W.M.O.; data
344 curation, N/A; writing, A.C.L., G.C. and W.T.L.; visualization, A.L. and G.C.; supervision W.M.O.;
345 project administration, W.M.O.; funding acquisition, W.M.O.

346 **Funding:** This research was funded the University of California, Office of the President/Tobacco-
347 Related Disease Research Program Emergency COVID-19 Research Seed Funding Grant (Grant
348 number: R00RG2369) to W.M.O. and the University of California, San Diego Academic Senate
349 Grant (Grant number: RG096651) to W.M.O.

350 **Conflicts of Interest:** The authors declare no conflict of interest.

351

352 **References**

- 353 1. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China,
354 2019. *N Engl J Med* 2020;382(8):727–733.
- 355 2. World Health Organization Regional Office For Europe. (2020). Retrieved from
356 <https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19>
- 357 3. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, Department of Pathology, Pathology Service, VA
358 San Diego Healthcare System San Diego, University of California San Diego, La Jolla, CA
359 92093, USAJ., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y.,
360 Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., ... Cao, B. (2020). Clinical features of
361 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* (London, England),
362 395(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)

363 4. Liu, K., Fang, Y., Deng, Y., Liu, W., Wang, M., & Ma, J. et al. (2020). Clinical characteristics
364 of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chinese Medical Journal*,
365 133(9), 1025-1031. <https://doi.org/10.1097/cm9.0000000000000744>

366 5. Xu XW, Wu XX, Jiang XG, et al. . Clinical findings in a group of patients infected with the
367 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case studies.
368 *BMJ* 2020; 368: m606. doi:10.1136/bmj.m606

369 6. Chen N, Zhou M, Dong X et al Epidemiological and clinical characteristics of 99 cases of
370 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;
371 395: 507–13

372 7. Yang X, Yu Y, Xu J et al Clinical course and outcomes of critically ill patients with SARS-
373 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
374 *Lancet Resp Med* 2020; 8: 475–81.

375 8. Gibson P, Qin L, Puah S. COVID -19 acute respiratory distress syndrome (ARDS): clinical
376 features and differences from typical pre- COVID -19 ARDS. *Medical Journal of Australia*.
377 2020;213(2):54. doi:10.5694/mja2.50674

378 9. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities and its effects in patients infected
379 with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious*
380 *Diseases*. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017

381 10. Pranata R, Huang I, Lim M, Wahjoepramono E, July J. Impact of cerebrovascular and
382 cardiovascular diseases on mortality and severity of COVID-19—systematic review, meta-
383 analysis, and meta-regression. *Journal of Stroke and Cerebrovascular Diseases*.
384 2020;29(8):104949. doi:10.1016/j.jstrokecerebrovasdis.2020.104949

385 11. Tian W, Jiang W, Yao J et al. Predictors of mortality in hospitalized COVID-19 patients: A
386 systematic review and meta-analysis. *J Med Virol*. 2020. doi:10.1002/jmv.26050

387 12. Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-
388 19 in Wuhan, China. *JAMA Cardiol*. <https://doi.org/10.1001/jamacardio.2020.0950> (2020).

389 13. Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus
390 disease 2019 (COVID-19). *JAMA Cardiol*. <https://doi.org/10.1001/jamacardio.2020.1017>
391 (2020).

392 14. Shi, S. et al. Characteristics and clinical significance of myocardial injury in patients with
393 severe coronavirus disease 2019. *Eur. Heart J*. 41, 2070–2079 (2020).

394 15. Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19:
395 immunity, inflammation and intervention. *Nat. Rev. Immunol*. 20, 363–374 (2020)

396 16. Vaninov, N. In the eye of the COVID-19 cytokine storm. *Nat Rev Immunol* 2020,
397 10.1038/s41577-020-0305-6, doi:10.1038/s41577-020-0305-6.

398 17. Connors, J.M. and Levy, J.H. (2020), Thromboinflammation and the hypercoagulability of
399 COVID-19. *J Thromb Haemost*, 18: 1559-1561. doi:[10.1111/jth.14849](https://doi.org/10.1111/jth.14849)

400 18. National Center for Health Statistics, & Centers for Disease Control and Prevention.
401 (2020). Retrieved from <https://www.cdc.gov/heartdisease/cardiomyopathy.htm>





402 19. Rose, Noel R. “Critical cytokine pathways to cardiac inflammation.” *Journal of interferon &*
403 *cytokine research : the official journal of the International Society for Interferon and Cytokine*
404 *Research* vol. 31,10 (2011): 705-10. doi:10.1089/jir.2011.0057





405 20. An, Na et al. “Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-
406 Inflammatory Marker in Cardiovascular Diseases.” *Frontiers in immunology* vol. 10 1592. 10
407 Jul. 2019, doi:10.3389/fimmu.2019.01592

- 408 21. Cheng Z., et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis
409 of non-ischemic dilated cardiomyopathy. *Redox Biology* vol 34. 2020, doi:
410 <https://doi.org/10.1016/j.redox.2020.101523>.
- 411 22. von Bruhl M.L. Monocytes, neutrophils, and platelets cooperate to initiate and propagate
412 venous thrombosis in mice in vivo. *J. Exp. Med.* 2012;209:819–835.
- 413 23. Brill A. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J. Thromb.*
414 *Haemost.* 2012;10:136–144.
- 415 24. Fuchs T.A. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. *Arterioscler.*
416 *Thromb. Vasc. Biol.* 2012;32:1777–
- 417 25. Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in
418 severe COVID-19 patients. *Natl Sci. Rev.* <https://doi.org/10.1093/nsr/nwaa041> (2020).
- 419 26. Zhang, D. et al. COVID-19 infection induces readily detectable morphological and
420 inflammation-related phenotypic changes in peripheral blood monocytes, the severity of
421 which correlate with patient outcome. Preprint at medRxiv
422 <https://doi.org/10.1101/2020.03.24.20042655> (2020).
- 423 27. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized
424 patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* (2020)
425 323:1061–9. doi: 10.1001/jama.2020.1585
- 426 28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP:
427 **Molecular signatures database (MSigDB) 3.0.** *Bioinformatics* 2011, **27**(12):1739-1740.
- 428 29. Shin JS, Greer AM. The role of FcεRI expressed in dendritic cells and monocytes. *Cell Mol*
429 *Life Sci.* 2015;72(12):2349-2360. doi:10.1007/s00018-015-1870-x
- 430 30. Mehta SY, Morten BC, Antony J, et al. Regulation of the interferon-gamma (IFN-γ) pathway
431 by p63 and Δ133p53 isoform in different breast cancer subtypes. *Oncotarget.*
432 2018;9(49):29146-29161. Published 2018 Jun 26. doi:10.18632/oncotarget.25635
- 433 31. Keating S, Maloney G, Moran E, Bowie A. IRAK-2 Participates in Multiple Toll-like Receptor
434 Signaling Pathways to NFκB via Activation of TRAF6 Ubiquitination. *Journal of Biological*
435 *Chemistry.* 2007;282(46):33435-33443. doi:10.1074/jbc.m705266200
- 436 32. Weber M, Gawanbacht A, Habjan M, et al. Incoming RNA virus nucleocapsids containing a
437 5'-triphosphorylated genome activate RIG-I and antiviral signaling. *Cell Host Microbe.*
438 2013;13(3):336-346. doi:10.1016/j.chom.2013.01.012
- 439 33. Wang C, Liu Z, Ke Y, Wang F: **Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the**
440 **Prostate and Prostate Cancer.** *Front Genet* 2019, **10**:12.
- 441 34. Hamanaka N. Eicosanoids in Mammals. *Comprehensive Natural Products Chemistry.*
442 1999:159-206. doi:10.1016/b978-0-08-091283-7.00153-3
- 443 35. Mukherjee S, Kumar R, Tsakem Lenou E, Basrur V, Kontoyiannis DL, Ioakeimidis F,
444 Mosialos G, Theiss AL, Flavell RA, Venuprasad K: **Deubiquitination of NLRP6**
445 **inflammasome by Cyld critically regulates intestinal inflammation.** *Nat Immunol* 2020,
446 **21**(6):626-635.
- 447 36. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN: **Chemokines**
448 **enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell**
449 **interaction.** *Nature* 2006, **440**(7086):890-895.
- 450 37. Szauter KM, Jansen MK, Okimoto G, Loomis M, Kimura JH, Heller M, Ku T, Tiirikainen M,
451 Boyd CD, Csiszar K et al: **Persistent Inflammatory Pathways Associated with Early**
452 **Onset Myocardial Infarction in a Medicated Multiethnic Hawaiian Cohort.** *Biochemistry*
453 *Insights* 2011, **4**.

- 454 38. Casson CN, Yu J, Reyes VM, Taschuk FO, Yadav A, Copenhaver AM, Nguyen HT, Collman
455 RG, Shin S: **Human caspase-4 mediates noncanonical inflammasome activation**
456 **against gram-negative bacterial pathogens.** *Proceedings of the National Academy of*
457 *Sciences* 2015, **112**(21):6688-6693.
- 458 39. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid
459 and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect.*
460 2020;9(1):761-770. doi:10.1080/22221751.2020.1747363
- 461 40. H.K. Kandikattu, S. Upparahalli Venkateshaiah, A. Mishra. Synergy of Interleukin (IL)-5 and
462 IL-18 in eosinophil mediated pathogenesis of allergic diseases. *Cytokine Growth Factor*
463 *Rev.*, 47 (2019), pp. 83-98
- 464 41. K.C. Verbist, K.D. Klonowski. Functions of IL-15 in anti-viral immunity: multiplicity and
465 variety. *Cytokine*, 59 (3) (2012), pp. 467-478
- 466 42. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
467 China. *Lancet Lond. Engl.* 395, 497–506 (2020).
- 468 43. Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress
469 syndrome. *Lancet Respir. Med.* 8, 420–422 (2020).
- 470 44. Bansal SS, Ismahil MA, Goel M, et al. Activated T Lymphocytes are Essential Drivers of
471 Pathological Remodeling in Ischemic Heart Failure. *Circ Heart Fail.* 2017;10(3):e003688.
472 doi:10.1161/CIRCHEARTFAILURE.116.003688
- 473 45. Bansal SS, Ismahil MA, Goel M, et al. Dysfunctional and Proinflammatory Regulatory T-
474 Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.
475 *Circulation.* 2019;139(2):206-221. doi:10.1161/CIRCULATIONAHA.118.036065
- 476 46. Blanton RM, Carrillo-Salinas FJ, Alcaide P. T-cell recruitment to the heart: friendly guests or
477 unwelcome visitors?. *Am J Physiol Heart Circ Physiol.* 2019;317(1):H124-H140.
478 doi:10.1152/ajpheart.00028.2019
- 479 47. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for
480 monocytes and macrophages. *Nat. Rev. Immunol.* 20, 355–362 (2020).
- 481 48. Yong Xiong, Yuan Liu, Liu Cao, Dehe Wang, Ming Guo, Ao Jiang, Dong Guo, Wenjia Hu,
482 Jiayi Yang, Zhidong Tang, Honglong Wu, Yongquan Lin, Meiyuan Zhang, Qi Zhang, Mang
483 Shi, Yingle Liu, Yu Zhou, Ke Lan & Yu Chen (2020) Transcriptomic characteristics of
484 bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients,
485 *Emerging Microbes & Infections*, 9:1, 761-770, DOI: 10.1080/22221751.2020.1747363
- 486 49. Chang TT, Chen JW. Emerging role of chemokine CC motif ligand 4 related
487 mechanisms in diabetes mellitus and cardiovascular disease: friends or foes?.
488 *Cardiovasc Diabetol.* 2016;15(1):117. Published 2016 Aug 24.
489 doi:10.1186/s12933-016-0439-9
- 490 50. Papoff, G., Presutti, D., Lalli, C. *et al.* *CASP4* gene silencing in epithelial cancer
491 cells leads to impairment of cell migration, cell-matrix adhesion and tissue
492 invasion. *Sci Rep* 8, 17705 (2018). <https://doi.org/10.1038/s41598-018-35792-8>
- 493 51. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. *Circulation.*
494 2020;141(20):1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941
- 495 52. Madjid, M., Safavi-Naeini, P., Solomon, S. D. & Vardeny, O. Potential effects of
496 coronaviruses on the cardiovascular system: a review. *JAMA Cardiol.*
497 <https://doi.org/10.1001/jamacardio.2020.1286> (2020).


- 498 53. Sweet ME, Cocciolo A, Slavov D, Jones KL et al. Transcriptome analysis of human heart failure reveals
499 dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart
500 failure. *BMC Genomics* 2018 Nov 12;19(1):812. PMID: [30419824](https://pubmed.ncbi.nlm.nih.gov/30419824/)
- 501 54. Sweet ME, Cocciolo A, Slavov D, Jones KL et al. Transcriptome analysis of human heart failure reveals
502 dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart
503 failure. *BMC Genomics* 2018 Nov 12;19(1):812. PMID: [30419824](https://pubmed.ncbi.nlm.nih.gov/30419824/)
- 504 55. RNA-seq of platelets from SARS-CoV-2 Covid-19. University of Utah 2020 May 22. Doi:
505 trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP262885
- 506 56. Chen, B.; Khodadoust, M.S.; Liu, C.L.; Newman, A.M.; Alizadeh, A.A. Profiling Tumor
507 Infiltrating Immune Cells with CIBERSORT. *Methods Mol Biol* 2018, 1711, 243–259,
508 doi:10.1007/978-1-4939-7493-1_12.






A


ICM and COVID-19: Overlapping Pathway Enrichment Scores




COVID-19 Platelet



ICM




COVID-19 Platelet




B


DCM and COVID-19: Overlapping Pathway Enrichment Scores




COVID-19 Platelet




COVID-19 Platelet




COVID-19 Platelet



DCM




A




Red = Inflammasome
Blue = Cytokine


B



C



D



E

